Literature DB >> 34011962

CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells.

Yo-Ping Lai1, Lu-Cheng Kuo1, Been-Ren Lin2, Hung-Ju Lin1, Chih-Yu Lin3, Yi-Ting Chen4, Pei-Wen Hsiao3, Huan-Tsung Chang5, Patrick Chow-In Ko6, Hsiao-Chin Chen7, Hsiang-Yu Chang5, Jean Lu8,9,10, Hong-Nerng Ho11,12, Betty A Wu-Hsieh12, John T Kung4, Shu-Ching Chen13.   

Abstract

CD28 is required for T cell activation as well as the generation of CD4+Foxp3+ Treg. It is unclear, however, how CD28 costimulation affects the development of CD8+ T cell suppressive function. Here, by use of Hepa1.6.gp33 in vitro killing assay and B16.gp33 tumor mouse model we demonstrate that CD28 engagement during TCR ligation prevents CD8+ T cells from becoming suppressive. Interestingly, our results showed that ectonucleotidase CD73 expression on CD8+ T cells is upregulated in the absence of CD28 costimulation. In both murine and human tumor-bearing hosts, CD73 is upregulated on CD28-CD8+ T cells that infiltrate the solid tumor. UPLC-MS/MS analysis revealed that CD8+ T cells activation without CD28 costimulation produces elevated levels of adenosine and that CD73 mediates its production. Adenosine receptor antagonists block CD73-mediated suppression. Our data support the notion that CD28 costimulation inhibits CD73 upregulation and thereby prevents CD8+ T cells from becoming suppressive. This study uncovers a previously unidentified role for CD28 costimulation in CD8+ T cell activation and suggests that the CD28 costimulatory pathway can be a potential target for cancer immunotherapy.

Entities:  

Year:  2021        PMID: 34011962     DOI: 10.1038/s42003-021-02119-9

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  40 in total

1.  Anergic T cells act as suppressor cells in vitro and in vivo.

Authors:  J G Chai; I Bartok; P Chandler; S Vendetti; A Antoniou; J Dyson; R Lechler
Journal:  Eur J Immunol       Date:  1999-02       Impact factor: 5.532

2.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

3.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

Authors:  L H Boise; A J Minn; P J Noel; C H June; M A Accavitti; T Lindsten; C B Thompson
Journal:  Immunity       Date:  1995-07       Impact factor: 31.745

4.  Anergic T cells as suppressor cells in vitro.

Authors:  G Lombardi; S Sidhu; R Batchelor; R Lechler
Journal:  Science       Date:  1994-06-10       Impact factor: 47.728

Review 5.  Signals and signs for lymphocyte responses.

Authors:  C A Janeway; K Bottomly
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

6.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

7.  CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis.

Authors:  A J Oliveira-dos-Santos; A Ho; Y Tada; J J Lafaille; S Tonegawa; T W Mak; J M Penninger
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

8.  An obligate cell-intrinsic function for CD28 in Tregs.

Authors:  Ruan Zhang; Alexandria Huynh; Gregory Whitcher; Jihoon Chang; Jonathan S Maltzman; Laurence A Turka
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

9.  T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression.

Authors:  C H June; J A Ledbetter; M M Gillespie; T Lindsten; C B Thompson
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

10.  Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo.

Authors:  M K Jenkins; R H Schwartz
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.